Object. The authors conducted an analysis of the distribution of glial cell line-derived neurotrophic factor in the human striatum following convection-enhanced delivery.
INCE the discovery, isolation, and sequencing of GDNF, 20 there has been considerable interest in its potential use as a regenerative therapy to reverse the clinical features of PD and prevent its progression. Delivery of this macromolecular protein has been problematic, however. Systemic delivery is ineffective given the inability of therapeutic amounts of GDNF to penetrate the blood-brain barrier. Intraventricular delivery was attempted in an early clinical trial but was limited by ineffective GDNF penetration into the brain and side effects; 27 subsequently, no clinical benefit was observed and this delivery route was abandoned. To overcome these limitations, GDNF, or a viral vector expressing GDNF, was distributed in the striatum using CED and was found to reverse parkinsonian symptoms in animal models of PD, 13, 17 which led to clinical trials in which GDNF was distributed in the putamen via CED.
Unlike intraventricular delivery and other methods that rely on diffusion for distribution, CED is not limited by an agent's molecular weight, concentration, or restricted diffusive properties. 7, 25 Convection-enhanced delivery permits a pressure-driven distribution of molecules directly within brain parenchyma via a cannula or catheter and can be used to target selected regions of the central nervous system (for example, deep brain nuclei) in a manner that bypasses the blood-brain barrier. Data from previous studies have also shown that CED can be used to distribute small and large molecules within the brain, brainstem, and spinal cord reliably, safely, and homogeneously over a wide range of volumes. 7, 19, [21] [22] [23] For macromolecules, the perfused tissue volume is related to the extracellular fluid fraction in the infused region of the central nervous system and to any tissue binding that may occur. 25 The outcomes of three clinical trials focused on the potential use of GDNF (molecular weight 30.1 kDa) for the treatment of PD have recently been published (henceforth denoted as the Bristol, Kentucky, and AmgenUT studies). 18, 28, 33 These trials are similar in that they all have relatively long-term (Ͼ 6 months) clinical follow ups, a com-mon drug source (Amgen), the same treatment target (the putamen), a similar total dose of GDNF, and evaluations of patient responses based on standardized assessments. Despite these similarities, authors of these trials reached contrasting conclusions regarding the efficacy of GDNF for the treatment of PD. The results of two small open-label studies 28, 33 indicated that local delivery of the neurotrophic factor leads to sufficient improvement in patient status to warrant further clinical investigation, whereas the findings of a more recent randomized controlled clinical trial 18 demonstrated no difference in the primary or secondary end points, leading the investigators to conclude that no significant clinical improvement was attained.
Factors that may have played a role in generating these divergent results include differences in drug delivery, neurotrophic effects not associated with GDNF per se (for example, sequelae stemming from the mechanical trauma of catheter placement 4 ), placebo effects in a small uncontrolled study, the presence or absence of controls, or sample size effects relating to the statistical power of each study. Based on published analyses of their data, however, it is clear that all three research groups 18, 28, 33 believed that differences in drug delivery might underlie the divergent clinical outcomes. Consequently, in the present report we analyzed the CED-based distribution of GDNF in the human striatum and evaluated the effects on drug distribution that arise from the use of different catheter geometries, infusion rates, and initial catheter placements in the clinical trials, ultimately determining whether these various delivery factors were responsible for the observed differences in trial outcomes.
Clinical Material and Methods

Drug Delivery Protocols Used in the Trials
To provide reference for the subsequent analysis and results, the drug delivery protocols in each of the clinical trials are summarized below.
Bristol Study. The GDNF-containing solution was continuously infused into the posterior putamen at 6 l/hour (0.100 l/minute) via a custom end-hole catheter with an outer diameter of 0.64 mm. The concentration of the infusate was 0.1 g/l during Months 12 to 18 of the trial and 0.2 g/l during Months 18 to 24 of the trial. 28 Kentucky Study. The GDNF-containing solution was continuously infused into the mid-putamen at 2 l/hour (0.0333 l/minute) via a multiport catheter with an outer diameter of 1.64 mm (model 10532, Medtronic) over a 24-week analysis. Superimposed on this infusion was a sequence of boli, each bolus being delivered over 117 seconds at 10.92 l/minute every 6 hours. The infusate concentration was 0.0226 g/l for the initial 8 weeks of the trial, 0.0752 g/l over the next 8 weeks, and 0.226 g/l during the last 8 weeks. 33 AmgenUT Study. The GDNF-containing solution was continuously infused into the posterior putamen at 6.25 l/ hour (0.104 l/minute) via an end-hole catheter (model 8760, Medtronic) with an outer diameter of 1.04 mm. The infusate concentration was 0.1 g/l during a 6-month trial. 18 
Calculating Drug Distribution
The drug distributions expected from the three trials were computed using a model in which the appropriate catheter was surrounded by an isotropic cylindrical tissue volume equivalent to that of the combined region of the human putamen, globus pallidus externus, and globus pallidus internus (Appendix). Infusate containing GDNF was described as initially entering the tissue from either an endhole catheter in the Bristol and AmgenUT studies or along a length of catheter corresponding to the location of multiple closely-spaced small holes in the Kentucky study. Fluid flow consisted of infusate pumped into the tissue together with a contribution from the uniform extrachoroidal production of cerebrospinal fluid. 1 The fluid was then considered to move by pressure-driven flow through the interstices of the tissue (that is, convective Darcy flow) to the tissue boundary between gray and white matter regions, with free convective flux accounting for mass flux across this interface. (Exact finite element representation of the gray-white matter boundary together with an extended description of anisotropic flow in the surrounding white matter is required only when considering GDNF concentration contours that closely approach the location of a gray-white matter boundary. 31 ) As GDNF moved through the interstitial space of the putamen and pallidum, it was modeled as subject to slow clearance across the microvasculature of the brain, dilution by extrachoroidally produced fluid, protein metabolism, and binding to the heparan sulfate moieties of the interstitial matrix.
14 The protein metabolism rate was estimated from the ELISA-measured GDNF concentration profile obtained after a 7-day point infusion of the neurotrophic factor at 0.1 l/minute.
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Catheter Choice and Fluid Delivery
A primary difference between the AmgenUT and Bristol studies was the use of single-port catheters of different diameters-that is, outer diameters of 1.04 mm (AmgenUT) compared with 0.64 mm (Bristol). From previous investigations 8, 15, 24 it is known that infusion pressure will push the tissue back from the catheter surface in a manner dependent on catheter diameter, inflow rate, and hydraulic conductivity and elastic modulus of the tissue, thus creating a tapered fluid annulus that allows retrograde flow to occur along a length of the catheter shaft. Accordingly, for the Amgen-UT and Bristol studies, we took this situation into account using a simple scaling formula (Appendix) to estimate the backflow distance in gray matter given the appropriate catheter diameter and volumetric inflow rate. Physically, fluid enters tissue not only across the fluid-tissue interface at the catheter tip, but also across the fluid-tissue interface that extends axially from the catheter tip to the maximum backflow distance. We noted that no significant difference in the volumetric inflow rate exists between the AmgenUT and Bristol studies as follows: 6.25 l/hour (0.104 l/minute, AmgenUT), compared with 6.0 l/hour (0.100 l/minute, Bristol).
Authors of the Kentucky study used a considerably different catheter (model 10532, Medtronic) and infusion protocol. The catheter diameter (1.65 mm) was larger than that in the other two studies, and fluid exited the catheter through 40 side ports arranged 10-in-a-row every 90˚ over a length of 5 mm, each row beginning approximately 2 mm from the catheter tip. 33 Because the spacing between the holes was only 0.5 mm and much shorter than the ultimate tissue penetration expected, modeling of inflow from this catheter was simplified by representing it as uniform flux across an equivalent cylindrical surface that is flush with the actual catheter surface and overlies the multiport region. The Kentucky study also differed from its Bristol and AmgenUT counterparts in that fluid delivery was not characterized by a constant rate of input but rather consisted of a sequence of 117-second 10.9-l/minute boluses superimposed every 6 hours onto a continuous basal inflow of 2 l/hour, or 0.033 l/minute. Our model retained the timing protocol of the experiment but ultimately separately examined the basal and periodic bolus components of the delivery for backflow effects.
Calculation of Drug Distribution
Computations were performed using version 3.1 of FEMLAB and version 4.1 of Mathematica. Brain region boundaries and associated magnetic resonance images were taken from the interactive Talairach atlas 34 (www.neurovia. umn.edu/cgi-bin/tal_atlas) and the Schaltenbrand and Wahren 32 atlas of the brain. Catheter locations (in Talairach mm coordinates) were {24.5, Ϫ11.4, 4} in the AmgenUT study, the end-hole target based on prior targeting in the Bristol study, 12, 18 and {22, 0, 4} in the Kentucky study as estimated from the average (center-port) positioning achieved in the 4-mm dorsoventral plane. 33 Infusate concentrations followed those of the individual protocols and were implemented as noted in Results. Figure 1A features the GDNF distributions computed for the AmgenUT and Bristol delivery protocols when the catheter tips in both trials were considered as located at the Talairach millimeter position {24.5, Ϫ11.4, 4}. The color distribution indicates the steady-state GDNF distribution expected for the AmgenUT trial as well as the 12-to 18-month portion of the Bristol study when both trials share a common flow rate and an infusate concentration of 0.1 g/ l. The red portion of the image denotes a free interstitial GDNF concentration equal to the infusate concentration. The outer color boundary identifies the extent of tissue penetration computed for a GDNF concentration of 3.3 nM or 0.1% of the AmgenUT infusate concentration. Note that this concentration is somewhat arbitrary with respect to a MEC for GDNF (see Discussion) but does indicate the approximate concentration level reached when the Amgen-UT or 12-to 18-month Bristol distribution encounters the nearest gray-white matter boundary in either the coronal (Fig. 1A upper) or axial ( Fig. 2 left, white circles) plane. The white contours in the upper and lower panels of Fig.  1A represent the additional tissue penetration that occurs (again to 3.3 nM) when the infusate concentration in the Bristol trial is doubled during the final 6 months, that is, months 18 to 24. The additional radial spread associated with doubling of the infusate concentration is approximately 1.0 mm. With catheters on target, the drug penetration achieved during the latter months of the Bristol trial was thus slightly greater than that achieved throughout the AmgenUT trial; there was a negligible difference during the initial 12 to 18 months of the Bristol trial. Both studies were predicted to dose at minimum the central posterior portion of the putamen with considerable additional exposure of the globus pallidus externus.
Results
AmgenUT and Bristol Study Drug Distributions
In practice not all catheters are positioned on target, and their associated GDNF distributions will scatter around the ideal. The positioning uncertainty is indicated in Fig. 2 right, which reveals the locations of catheter tip placements in the coronal plane containing the largest number of points observed in the AmgenUT trial (that is, 26 of 68 total catheter placements). The standard deviation for the radial coordinate was estimated as 2.8 mm for these placements and was similar to the positioning uncertainty in the pilot Bristol trial (R. Coffey, Medtronic, Inc., personal communication). It has a magnitude similar to the radius of the 3.3-nM GDNF contour computed for an on-target AmgenUT or 12-to 18-month Bristol catheter ( Fig. 2 right, white outline), indicating that for some catheters a high fraction of the drug distribution volume can lie beyond the putaminal border.
The diameters of the AmgenUT and Bristol catheters differed by nearly twofold, potentially leading to a difference in GDNF distribution because fluid backflow along the catheter is affected by this parameter. 8, 24 Simulations for the larger AmgenUT catheter, when placed exactly on target, are represented in Fig. 3 ; the left panel shows the distribution expected at the flow rate of 0.1 l/minute when backflow along the catheter is allowed. In this simulation, fluid enters the tissue not only across the hemispherical surface at the bottom of the catheter (near axial coordinate z = 0) but also across a 0.005-mm-thick annulus with a length of 3.0 mm (see Appendix for backflow length scaling formula). The annulus is too thin to appear on the scale represented in Fig. 3 , although the influence of backflow is apparent as a teardrop-shaped red region in the immediate vicinity of the catheter surface (left panel). Figure 3 right features the distribution when fluid backflow is absent. Distribution near the catheter tip (red region) now exhibits some forward flow and is generally more spherical than when backflow is present. Importantly, however, the shape of the GDNF distribution limits, in both cases, to very similar profiles for all regions of concentration beyond 15% of the infusate concentration (that is, beyond a blue contour with a 3.5-mm radius). Indeed, distant concentration distributions become nearly superimposable provided that the end-hole catheter image (Fig. 3 right) is translated upward by just 0.7 mm. In the case of the Bristol catheter, the diameter was smaller, the backflow length was only 70% of that of the AmgenUT catheter, and the GDNF concentration was intermediate between those exhibited in Fig. 3 . Consequently, at the infusion rate of 0.1 l/minute that was used in both trials and for catheters placed exactly on target, negligible differences in GDNF distribution due to backflow are predicted to exist between the AmgenUT and Bristol trials for all spatial regions beyond 15% of the infusate concentration.
An additional role for backflow in both trials becomes apparent when the uncertainty of tip location is introduced. As seen in the AmgenUT distribution represented in Fig. 2 , approximately one quarter of the initial placements lie sufficiently close to the putamen-internal capsule boundary to allow the backflow annulus about a dorsoventrally oriented catheter to extend into the white matter and shunt some drug into that tissue region, away from the target.
Kentucky Study Drug Distributions
Analysis of the Kentucky trial began with a consideration of the effects of fluid backflow on delivery. At the continuous basal flow rate of 0.033 l/minute, backflow was negligible and all fluid that crossed the catheter-tissue interface in the multiport region was initially retained in the tissue and percolated through it. This finding follows from a consideration of the backflow length (x m ) predicted for this basal inflow rate had the fluid not been infused through the multiport catheter actually used, but rather through an end-hole catheter of the same outer diameter. An evaluation of Equation 1 in the Appendix predicts a backflow length of 2.0 mm. Given that this length is far shorter than the 5 mm over which the multiple ports were distributed on the model 10532 Medtronic catheter, one can conclude that fluid backflow is negligible at the basal rate of inflow.
During the bolus portions of delivery, however, the volumetric rate of infusion rose to 10.9 l/minute. Insertion of this rate into Equation 1 predicted a backflow length of more than 50 mm. This estimate is crude because the formula was derived for an end-hole catheter design rather than the multiport design and, more importantly, is here being applied to a flow rate and catheter pair outside the range of original experimental calibration. Nonetheless, the estimate far exceeds the 5 mm of the multiport distribution and suggests that fluid associated with the bolus inputs is likely subject to backflow and distribution into white matter regions lying above the putamen/globus pallidus nuclei. The drug mass that follows this flow and is lost to the putamen cannot be accurately calculated at present, but some guidance for this bolus component may be obtained from observations in the rat striatum in which infusions via 28-gauge stainless-steel catheters at both 1 and 5 l/minute led to extrastriatal distribution of approximately 30% of the infused mass.
Consequently, in an attempt to bracket actual GDNF distribution, particularly its radial spread, we looked at GDNF distributions for two simulations of the Kentucky protocol as follows: one in which only the basal inflow rate was taken into account (Fig. 1B left panels) , and computations reflected the concentration distributions that would develop if all bolus fluid were lost to backflow; and another in which backflow was set aside, and both bolus and basal inflow components were retained (Fig. 1B right panels) . These GDNF distributions were computed for the highest infusate concentration (0.23 g/l or 7.5 M) used in the Kentucky protocol (final 8 weeks) and thus indicated the deepest tissue penetrations achieved in that trial. Concentration distributions were computed for both coronal (Fig. 1B upper panels) and sagittal (Fig. 1B lower panels) views, with the catheter tip located at Talairach millimeter position {22, 0, 4}. To allow comparisons with the previous AmgenUT and Bristol distributions, the outer boundary of these distributions was again defined by the 3.3-nM level used previously. (Note, however, that the same absolute concentration of the AmgenUT/Bristol trials and the Kentucky trial does not occur at the same color given that plot colors are based on different concentration scales because of the twofold greater infusate concentration of the 16-to 24-week Kentucky trial relative to that of the AmgenUT or 12-to 18-month Bristol trials.)
Contrast the right and left panels of each view in Fig. 1B to note the maximum by which the distribution volume, estimated on the basis of full retention of infused fluid by the gray matter of the putamen/globus pallidus nuclei, can be reduced by bolus backflow losses. The actual distribution volume lies between those represented in the two panels and may be closer to the full retention case. In this case the transverse dimensions of the infusate volume for the 16-to 24-week period of the Kentucky study exceeded but were comparable with those attained using the AmgenUT or early-phase Bristol protocols (compare Fig. 1A upper with Fig. 1B upper right) .
With the catheter perfectly positioned, the primary difference between the AmgenUT/Bristol and Kentucky concentration distributions was the location given the use of differing targeting coordinates. In the coronal and sagittal planes passing through the catheter tip location, the GDNF distributions occupied much the same area relative to nuclear boundaries as those computed for the AmgenUT trial (compare Figs. 1A and B) , but this situation did not hold for the axial plane (Fig. 2 left) . In this plane the Kentucky target was located just anterior to the mid-putamen, whereas the AmgenUT/Bristol target was more posterior. Consequently, at a contour level of 3.3 nM, the computed GDNF distribution for the Kentucky trial with bolus fluids lost to backflow (Fig. 2 left, yellow line) fell short of that for the AmgenUT or 12-to 18-month Bristol trial (Fig. 2 left, white  line) . With full retention of bolus fluids in the gray matter, the 3.3-nM contour of the Kentucky trial (Fig. 2 left, blue  line) nears that of the AmgenUT/Bristol trials. Thus, for a sufficiently high choice of outer contour concentration (taken as a minimum effective drug concentration) and with catheters positioned on target, some portions of the putamen would receive different exposures according to whether the drug was administered based on the AmgenUT/Bristol or Kentucky protocol.
Lastly, Fig. 2 left features the locations of catheter tip placements as mapped by Slevin et al. 33 to a single (ϩ4 mm) axial plane but further modified by transposing all locations to the right side of the brain only. The variability in the distribution of these placements was comparable with that of the AmgenUT or Bristol trials except that no placements were close to the gray-white putaminal boundary, which indicated little potential for drug shunting to the white matter at the basal flow rate.
Discussion
The goals of our analysis were as follows: 1) to characterize the distribution of GDNF in the human striatum using CED; and 2) to determine whether differences in drug delivery in the AmgenUT, Bristol, and Kentucky clinical trials were a likely cause of the reported differences in clinical outcome. Authors of two of these trials, Bristol and Kentucky, concluded that GDNF is efficacious in reducing the symptoms of PD, whereas researchers in the AmgenUT trial found no clinical utility. To evaluate these differences, we first considered their implications in the ideal situation, when all catheters are positioned on target. We then considered the implications when position scatter was taken into account.
If all catheters were positioned on target and the different outcomes of the trials were taken at face value, then a critical volume of tissue must have existed that was dosed to favorable response in the Kentucky and Bristol infusions but not in the AmgenUT infusions. For a particular choice of MEC of GDNF (for example, 3.3 nM) applied to all three trials, Figs. 1A and 2 indicate that such a volume would have had to bridge and overlap portions of the Kentucky and 18-to 24-month Bristol distributions, yet have its posterior edge limited to a location within the shell of tissue lying between the AmgenUT and 18-to 24-month Bristol MEC contours.
In contrast, if uncertainty in the initial catheter positioning was taken into account, two component effects on expected response could be identified. First, for that portion of positioning uncertainty that excluded the scatter of tip locations to regions near the putaminal boundary, the 2.8-mm radial positioning error for the AmgenUT and Bristol trials, relative to the shell thickness between the Amgen-UT and Bristol 18-to 24-month trials (~ 1 mm in Fig. 1A) , implied that considerable dispersion would occur in the effective dosing of the critical volume across both treated populations. This component of scatter therefore diminished the differential response between these two trials, even suggesting difficulty in obtaining a statistically significant measure of this difference. Moreover, the positioning uncertainty included a component that accounts for the placement of some catheter tips close to the gray-white border of the putamen. In the AmgenUT trial, a substantial fraction of the catheter tips were sufficiently near these borders to allow the establishment of 3-mm backflow annuli to the white matter (Fig. 2 right) . Because a drug can be heavily rerouted along white matter tracks when this situation occurs, 8, 24 patients with this border placement would not have properly controlled delivery of the drug to the putamen and should therefore be removed from the sample population evaluated for response. In turn, this finding suggested that a statistical reanalysis of the (large trial) AmgenUT data is in order; with these patients removed, the statistical power of the AmgenUT study would be reduced, as would the confidence with which GDNF is considered to have no significant effect. (Note that this subtraction would be a sample reduction in addition to the one previously reported in which censored patients were those whose catheters moved from their initial placements. 18 
)
The most unique drug distribution of the three trials was that predicted for the Kentucky target, which arose from the researchers' use of a multiport catheter and their choice of input flows and target site. As expected, our simulations for this multiport configuration (Fig. 1B right panels , base flow ϩ bolus flow) revealed that a great deal of cylindrical symmetry was present in the GDNF distribution; for example, the axial/radial aspect ratio (as measured from the center port position) is 1.4, a contour corresponding to an interstitial to infusate concentration ratio of 50%. By the 1% contour, however, the aspect ratio was near unity, cylindrical symmetry was lost, the radial spread was approximately 5.3 mm, and the distribution developed a spherical/ elliptical shape nearly identical to that obtained using an end-hole catheter. At this contour, the GDNF concentration can generally be expected to retain biological activity. Thus, except for axial spreading related to backflow effects, the outer shape (not necessarily the extent) of the infused volume did not differ between the AmgenUT/Bristol and Kentucky protocols; however, the putaminal subregions in which these distributions developed did differ because of catheter targeting differences.
Our simulations of the Kentucky protocol indicated that the choice of a relatively high flow rate of 10.9 l/minute during the bolus phase of drug delivery is likely to lead to some backflow along the catheter and loss of some GDNF from the target tissue to more distant tissue volumes in humans. This finding is consistent with previous observations in the nonhuman primate 2 in which 10.5-l pulses of GDNF were infused intraputaminally (presumably with a pulse length of 2 minutes as used in the human trial and thus with a slightly smaller inflow rate of 5.3 l/minute). In this case, Ai et al. 2 reported backflow along the catheter as evidenced by GDNF immunostaining to the point of insertion in the frontal cortex and substantial staining in structures well above the catheter tip including the corpus callosum and white matter adjacent to the frontal cortex. This observation is also consistent with our formula for backflow distance (Equation 1). If it is reevaluated for the nonhuman primate using Ai and associate's catheter diameter of 1.0 mm and a 5.3-l/minute flow rate, a backflow distance of 27 mm is predicted, a value that exceeds the distance from the catheter tip to catheter intersection with the dorsal surface of the putamen and suggests the existence of a backflow annulus extending at least to the corpus callosum and providing an exit route for a portion of the bolusinfused fluid. As mentioned previously, the amount of drug mass that accompanied this loss was not accurately known but could exceed 20% of the total (base ϩ bolus components) administered in the Kentucky protocol.
Note that previous authors have reported the extent of tissue distribution when GDNF was delivered to the nonhuman primate putamen by a protocol similar to the one used in the Kentucky human trials. 2 Based on GDNF immunostaining these authors reported mean tissue penetrations on the order of 8 mm up to a maximum of 11 mm, whereas we estimated 5.3 mm as the maximum transverse penetration distance at the 3.3-nM concentration contour (no bolus fluids lost to backflow; Fig. 1B right panels) . This comparison tends to validate an approximate order of magnitude likeness for the human and primate situations. Furthermore, the volume of distribution corresponding to our computed radius was 625 mm 3 , a value that approaches the 1000-mm 3 volume of distribution reported by Gash et al. 11 However, a more refined comparison was not feasible given the absence of an established quantitative relationship between the intensity of the peroxidase-avidinbiotin GDNF immunostaining and absolute concentration values of GDNF (such as our 3.3-nM contour concentration).
The effective range of GDNF distribution is not well known presently. Ultimately, the extent of an effective concentration depends on the choice of either a concentration threshold or an area-under-the-curve type of metric that accounts for target tissue response. Accurate in vivo estimates of these quantities are unavailable because the mechanism involving the binding of GDNF to both glycosylphosphatidylinositol-linked GDNF family coreceptor (GFR␣1) and heparan sulfate moieties associated with the plasma membrane and any interactions between these two bound forms of GDNF have not been fully characterized. Nonetheless, initial limits for the MEC are suggested by the low-affinity binding constant (Kd = 2.2 nM) associated with GDNF binding to plasma membrane-coupled heparan sulfate on the surface of cells of the Madin-Darby canine kidney cell line (transfected to also express both GFR␣1 and a receptor tyrosine kinase, cRET) 5 or a similar constant (Kd = 0.33 nM) reported for transfected Neuro-2a cells in culture. 16 A still lower binding constant has been reported for the GFR␣1 receptor alone. Moreover, a concentration of 100 ng/ml (3.3 nM) has been reported as sufficient for the promotion of axon sprouting in cultured ganglia as well as for the neurite outgrowth from cultured PC12 cells. 5, 9 These nanomoles/liter-level concentrations are approximately 0.001 of the infusate concentration used in the AmgenUT trial, and if actually applicable to human putamen in vivo, suggest that GDNF remained active in tissue out to the 0.1% contour of that trial. It is this contour that has been used in the present work to define the likely penetration depth of GDNF in human tissue. In contrast, other factors may cause the MEC to be greater than a few nanomoles/liter. One consideration is that GDNF affinities for heparan sulfate vary greatly with the particular tissue source of the heparan sulfate. 3 If this binding is relatively weak in the primate brain yet still required as part of the GDNF signaling mechanism, then it is possible that higher GDNF concentrations are necessary for effect. In the case of renal morphogenesis studies in which tissues were depleted of glycosaminoglycans, the MEC rose 10-fold to 1000 ng/ml (33 nM). 29 Another consideration is whether a larger GDNF concentration is required to ensure sufficient retrograde transport from the putaminal delivery site to the cells of the substantia nigra. If, because of factors such as these, minimum effective GDNF concentrations in the brain rise to the 100-nM range or higher, then the contours that mark maximum effective spread in the brain will begin to differ from those in Figs. 1 and 2 , but such differences are not expected to be great because of the steepness that develops at the very edge of the concentration profile due to strong binding of GDNF to heparan sulfate.
Conclusions
In summary, our computations produced estimates of the CED-and diffusion-based distribution of GDNF in the human putamen. We showed that when catheters are positioned exactly on target, the GDNF distribution volume for the Kentucky trial (on an either basal or total flow basis) is spatially shifted from those for the AmgenUT and Bristol trials, whereas only minor differences exist between the AmgenUT and Bristol volumes. Based on this drug delivery, it is difficult to rationalize the apparently positive Kentucky and Bristol outcomes and the negative AmgenUT outcome; perhaps the explanation resides in the widely varying statistical powers of the studies. With regard to the larger-scale AmgenUT trial, we identified a number of catheter placements associated with a high probability of backflow and reduced delivery to the target tissue. (Placements in the Bristol trial might also need review for similar effects.) This finding suggests the need to exclude these data from the treatment population and reestimate the statistical power of the AmgenUT trial for the purpose of determining whether the divergent Bristol and AmgenUT outcomes are statistically consistent at any level of useful response. An exact determination of the efficacy of the Kentucky protocol may require a separate trial because of its unique catheter siting.
Appendix
Backflow Distance Along Catheter
When fluid is pumped into a tissue from an end-hole catheter, the associated pressure not only drives fluid through the interstitial space but also creates a small annulus around the catheter, allowing for backflow of fluid through this ring. Infusate then enters tissue not only across the fluid-tissue interface at the very tip of the catheter, but also across the fluid-tissue interface of the annulus. 8, 24 The length of the annulus through which backflow occurs (x m ) depends on the radius of the catheter (r c ), the volumetric infusion rate (Q), a characteristic dimension of the tissue volume being infused (L), and the hydraulic conductivity and elastic modulus of the tissue. For the human putamen, the backflow length x m has been estimated from the equation
(1) where x m , r c , and L (= 3.9) are represented in centimeters and Q is measured in microliters/minute. This formula is based on our prior work 24 but differs slightly given the inclusion of the log term that explicitly accounts for tissue dimension (and correction of a small numerical error in the original). Backflow lengths are very insensitive to small changes in L and hence to the details of catheter positioning as encountered in our set of clinical trials.
Fluid and Mass Transport of GDNF in the Brain
Geometry. Tissue of the human putamen and globus pallidus was approximated using an equivalent tissue cylinder. The height was taken to be 1.8 cm, and the radius was varied from 0.65 (the nearest distance to a gray-white interface from the AmgenUT/Bristol catheter tip) to 1 cm (an arbitrarily larger value allowing examination of the effects on concentration distribution by boundary location). The catheter was positioned along the axis of the cylinder, and the catheter tip (AmgenUT or Bristol) or the midpoint of the multiport catheter (Kentucky) was centered within the cylinder. In the case of the end-hole catheter, a thin fluid-filled annulus with a length equal to the appropriate x m backflow distance was placed concentrically around the catheter; the annulus tapered from a width of h o at the catheter tip to zero at x m ; in addition, a small fluid-filled hemisphere of radius r c ϩ h o was centered on the tip to account for tissue displacement. In the case of the multiport catheter, there was no annu-lus, and fluid was delivered uniformly over the section of catheter corresponding to the location of the 40 ports. Note that concentration distributions (down to 0.1% of the infusate concentration [C inf ]) within the cylindrical tissue regions were found to be insensitive to boundary location. There was some flaring open of the lower-valued concentration contours when they intersected the boundary of the smaller-radius cylinder, but the numerical values of these contours away from the immediate surface differed only slightly from the corresponding contours computed for the larger cylinder.
Fluid Transport. For the end-hole catheter, infusate develops a Poiseuille velocity profile within the catheter and thus crosses the base of the hemisphere at the tip with a parabolic radial profile consistent with the 0.1-l/minute volumetric inflow rate of the AmgenUT and Bristol protocols. Fluid velocities (u ns ) and pressures (P) within the hemispheric and annular regions are described by the stationary Navier-Stokes equation expressing the differential conservation of momentum for an isothermal and incompressible fluid, 
where and are density and viscosity, respectively, and external body forces have been neglected. Boundary conditions for the Navier-Stokes space include the no-slip condition on the outside surface of the catheter, symmetry along the catheter axis, equality between the Navier-Stokes and Darcy pressures at the fluid interface with surrounding tissue, and the use of the viscous form of the stress tensor. 10 For all catheters, the gray matter region surrounding the catheter is modeled as an isotropic consolidated porous medium in which the stationary equation of continuity
where u dl is the average velocity in the tissue and F is the extrachoroidal rate of fluid production (0.18 l/g/min), 1 is combined with fluid velocities described by the Darcy law; 10, 24, 25 that is,
where P is the interstitial pressure, k is the permeability within the porous medium, and the hydraulic conductivity of the tissue is k/. Boundary conditions for the Darcy space include symmetry along the catheter axis, zero pressure (relative to the cerebrospinal fluid pressure) at the outside surfaces of the tissue cylinder, and the normal flux boundary condition at the fluid-tissue interfaces. For the end-hole catheter, Ϫn · u dl = Ϫn · u ns ,
where n denotes the outward normal to the Darcy volume, and u ns is available from Equation 2; and for the multiport catheter, Ϫn · u dl = Ϫn · u mp , (6) where u mp = Q/(2r c l)e r is the radially directed velocity across the port section of the catheter, and l is the length of this section.
Mass Transport of GDNF. For the end-hole catheter, a differential mass balance must be written for the annulus as well as for the tissue region. Only the balance within the tissue region is required for the multiport catheter. Within the annular fluid space, no sinks are present and only convection and diffusion are operative so that mass balance is described by ‫ץ‬c a /‫ץ‬t = D aq ٌ 2 c a Ϫ ٌ · (u ns c a ), 
